J 2024

Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

EKANEM, Emmanuel; Petr NEUZIL; Tobias REICHLIN; Joseph KAUTZNER; van der Voort PEPIJN et al.

Základní údaje

Originální název

Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

Autoři

EKANEM, Emmanuel; Petr NEUZIL; Tobias REICHLIN; Joseph KAUTZNER; van der Voort PEPIJN; Pierre JAIS; Gian-Battista CHIERCHIA; Alan BULAVA; Yuri BLAAUW; Tomas SKALA; Martin FIALA; Mattias DUYTSCHAEVER; Gabor SZEPLAKI; Boris SCHMIDT; Gregoire MASSOULLIE; Kars NEVEN; Thomas OLIVIER; Johan VIJGEN; Estelle GANDJBAKHCH; Daniel SCHERR; Arne JOHANNESSEN; David KEANE; Serge BOVEDA; Philippe MAURY; Ignacio GARCIA-BOLAO; Ante ANIC; Peter Steen HANSEN; Franck RACZKA; Antoine LEPILLIER; Yves GUYOMAR; Dhiraj GUPTA; Van Opstal JURREN; Pascal DEFAYE; Christian STICHERLING; Philipp SOMMER; Pavel KUCERA; Joaquin OSCA; Fariborz TABRIZI; Antoine ROUX; Michael GRAMLICH; Stefano BIANCHI; Pedro ADRAGAO; Francesco SOLIMENE; Claudio TONDO; Antonio Dello RUSSO; Juergen SCHREIECK; Armin LUIK; Obaida RANA; Gerrit FROMMEYER; Frederic ANSELME; Ingo KREIS; Raphael ROSSO; Andreas METZNER; Laszlo GELLER; Samuel H BALDINGER; Angel FERRERO; Stephan WILLEMS; Andreas GOETTE; Greg MELLOR; Shibu MATHEW; Lukasz SZUMOWSKI; Roland TILZ; Saverio IACOPINO; Peter Karl JACOBSEN; Andrikopoulos GEORGE; Pavel OSMANCIK; Stefan SPITZER; Richard BALASUBRAMANIAM; Abdul Shokor PARWANI; Thomas DENEKE; Andrzej GLOWNIAK; Antonio ROSSILLO; Helmut PUERERFELLNER; David DUNCKER; Peter REIL; Thomas ARENTZ; Daniel STEVEN; Juan Jose OLALLA; Jonas S S G DE JONG; Reza WAKILI; Selim ABBEY; Gottschling TIMO; Antonio ASSO; Tom WONG; Bertrand PIERRE; Niels Christian EWERTSEN; Leonard BERGAU; Cristina LOZANO-GRANERO; Maximo RIVERO; Alexander BREITENSTEIN; Jaakko INKOVAARA; Samir FAREH; Decebal Gabriel LATCU; Dominik LINZ; Patrick MUELLER; Javier RAMOS-MAQUEDA; Thomas BEIERT; Sakis THEMISTOCLAKIS; Dirk Grosse MEININGHAUS; Guenter STIX; Stylianos TZEIS; Jakub BARAN; Henrik ALMROTH; Daniel Rodriguez MUNOZ; de Sousa JOAO; Michalis EFREMIDIS; Pawel BALSAM; Jan PETRU; Thomas KUEFFER; Petr PEICHL; Lukas DEKKER; Domenico G DELLA ROCCA; Ondrej MORAVEC; Moritoshi FUNASAKO; Sebastien KNECHT; Gael JAUVERT; Julian CHUN; Romain ESCHALIER; Anna FUETING; Alexandre ZHAO; Pieter KOOPMAN; Mikael LAREDO; Martin MANNINGER; Jim HANSEN; Daniel HARE; Anne ROLLIN; Zrinka JURISIC; Thomas FINK; Corentin CHAUMONT; Andreas RILLIG; Melanie GUNAWERDENE; Claire MARTIN; Bettina KIRSTEIN; Karin NENTWICH; Heiko LEHRMANN; Arian SULTAN; Jan BOHNEN; Mohit K TURAGAM a Vivek Y REDDY

Vydání

Nature Medicine, BERLIN, Nature Research, 2024, 1078-8956

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 50.000

Označené pro přenos do RIV

Ne

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

atrial fibrillation; pulsed field ablation

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 4. 4. 2025 12:40, Mgr. Tereza Miškechová

Anotace

V originále

Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for similar to 1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.